跳至主要内容
临床试验/NCT05783804
NCT05783804招募中不适用

Plaque Reversal With Early, Aggressive Lipid Lowering Therapy

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年7月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
1
主要终点
CAD Progression

研究概览

简要总结

This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with heterozygous familial hypercholesterolemia
  • Adult between 18 and 50 years old
  • LDL cholesterol levels above 100 mg/dl (>2.6 mmol/L) at inclusion

排除标准

  • Renal insufficiency, defined as eGFR < 30 ml/min
  • History of atherosclerotic cardiovascular events
  • Atrial fibrillation
  • Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
  • Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

结局指标

主要结局

CAD Progression

时间窗: 40 Weeks

Difference in total plaque volume between the initial and follow-up CCTA scan

次要结局

  • Non-calcified plaque progression(40 Weeks)
  • Calcified plaque progression(40 Weeks)
  • Number of high-risk plaques(40 Weeks)
  • Difference in Pericoronary Adipose Tissue Attenuation(40 Weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

E.S.stroes

Prof. dr. E.S.G. Stroes, MD, PhD.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

研究点 (1)

Loading locations...

相似试验